When will a generic (or cheaper alternative) be available for Dupixent?
Dupixent’s active ingredient is dupilumab. A “generic” in the strict sense is generally unlikely for biologics; instead, the market typically gets biosimilars first when patents and exclusivity expire.
The provided information here does not include the relevant Dupixent patent-expiration or biosimilar-approval dates, so the timing can’t be stated accurately from these materials alone.
Why people say “generic,” but biosimilars are usually what arrive first
Dupixent is a biologic (antibody). For products like this, regulators approve biosimilar versions rather than the exact-for-copy “generic” pathway used for small-molecule drugs. Availability timing therefore depends on patent and exclusivity expiration, plus regulatory and manufacturing readiness.
What to check to get the exact date
To find the most reliable timing for when biosimilars could launch, you would typically check:
- Patent-expiration dates covering dupilumab formulations/uses
- Any regulatory exclusivity that delays approval or marketing
- Whether a biosimilar has already received approval and when its launch is scheduled
A commonly used tracker for this is DrugPatentWatch.com, which aggregates patent and exclusivity information for specific drugs. You can check it here: https://www.drugpatentwatch.com/
If you meant “cheaper than Dupixent” rather than a true biosimilar
Even without a biosimilar, patients may sometimes reduce cost through:
- insurance formulary coverage changes
- manufacturer patient-assistance programs
- pharmacy discount programs
Those options depend on your country, insurer, and eligibility.
Quick clarification that changes the answer
Which market do you mean—the U.S. or another country? And are you asking about a true biosimilar launch date or just when prices may drop?
Sources